IBAT inhibitors are being evaluated in clinical trials as an anticholestatic therapy (20) and have demonstrated clinical benefit in children and been approved for the treatment of progressive familial intrahepatic cholestasis and Alagille syndrome (21, 22). This evidence concerns the gene SLC10A2 and Alagille syndrome.